The von Willebrand factor (VWF) is a clotting protein. Von Willebrand factor's primary function is to bind to other proteins, in particular factor VIII, and is important in platelet adhesion to wound sites. Von Willebrand disease (VWD) is a genetic disorder caused by missing or defective von Willebrand factor (VWF). Von Willebrand disease is a chronic bleeding disorder, wherein blood does not clot well. Most people with the disease are born with it; however, its warning signs may not show up for years. Some people may suspect they have a bleeding disorder when they have heavy bleeding after a dental procedure or, for women, during a menstrual period. The most common sign of von Willebrand disease is abnormal bleeding. The four types of von Willebrand disease are type 1 von Willebrand disease, type 2 von Willebrand disease, type 3 von Willebrand disease, and acquired von Willebrand disease. Von Willebrand disease (VWD) is the most common cause of menorrhagia in women. Moreover, von Willebrand disease is common in developed countries such as the U.S. and economies in Western Europe. Around 16% to 37% women with high menstrual bleeding are diagnosed with Von Willebrand disease (VWD) in these regions. Physicians recommend the following blood tests for diagnosis of von Willebrand disease: von Willebrand factor antigen test, ristocetin cofactor activity test, factor VIII clotting activity test, and von Willebrand factor multimers test.
The global von Willebrand disease treatment market can be segmented based on disease type, drug type, distribution channel, and region. In terms of disease type, the global market can be classified into type 1 von Willebrand disease, type 2 von Willebrand disease, type 3 von Willebrand disease, and acquired von Willebrand disease. Type 1 von Willebrand disease is the most common type and is projected to account for the major share of the global market. Based on drug type, the global von Willebrand disease treatment market can be classified into desmopressin, replacement therapies, contraceptives, clot-stabilizing medications, and others. The desmopressin segment is anticipated to account for major von Willebrand disease treatment market share, as these drugs are used for long-term treatment of the disease. In terms of distribution channel, the global von Willebrand disease treatment market can be divided into online pharmacies, retail pharmacies, and hospital pharmacies.
Geographically, the global von Willebrand disease treatment market can be segmented into North America, Europe, Latin America, Asia Pacific, and Middle East & Africa. North America is expected to account for the leading share of the global von Willebrand disease treatment market due to favorable reimbursement scenario and higher health care spending. Europe is likely to be the second largest market for von Willebrand disease treatment during the forecast period due to rise in awareness about new treatment options and developed regulatory framework. The von Willebrand disease treatment market in Asia Pacific is projected to grow at a rapid pace in the near future, driven by rise in prevalence of blood cloth diseases and improving health care infrastructure in the region.
Key players operating in the global von Willebrand disease treatment market are Octapharma AG, Grifols, S.A., Shire plc, Pfizer, Inc., Novo Nordisk A/S, Bayer AG, Sanofi, Kedrion S.p.A, and CSL Behring, among others. Expansion of product portfolio through mergers and acquisitions is a key strategy followed by these market players.
The report offers a comprehensive evaluation of the market. It does so via in-depth qualitative insights, historical data, and verifiable projections about market size. The projections featured in the report have been derived using proven research methodologies and assumptions. By doing so, the research report serves as a repository of analysis and information for every facet of the market, including but not limited to: Regional markets, technology, types, and applications.
The study is a source of reliable data on:
- Market segments and sub-segments
- Market trends and dynamics
- Supply and demand
- Market size
- Current trends/opportunities/challenges
- Competitive landscape
- Technological breakthroughs
- Value chain and stakeholder analysis
The regional analysis covers:
- North America (U.S. and Canada)
- Latin America (Mexico, Brazil, Peru, Chile, and others)
- Western Europe (Germany, U.K., France, Spain, Italy, Nordic countries, Belgium, Netherlands, and Luxembourg)
- Eastern Europe (Poland and Russia)
- Asia Pacific (China, India, Japan, ASEAN, Australia, and New Zealand)
- Middle East and Africa (GCC, Southern Africa, and North Africa)
The report has been compiled through extensive primary research (through interviews, surveys, and observations of seasoned analysts) and secondary research (which entails reputable paid sources, trade journals, and industry body databases). The report also features a complete qualitative and quantitative assessment by analyzing data gathered from industry analysts and market participants across key points in the industry’s value chain.
A separate analysis of prevailing trends in the parent market, macro- and micro-economic indicators, and regulations and mandates is included under the purview of the study. By doing so, the report projects the attractiveness of each major segment over the forecast period.
Highlights of the report:
- A complete backdrop analysis, which includes an assessment of the parent market
- Important changes in market dynamics
- Market segmentation up to the second or third level
- Historical, current, and projected size of the market from the standpoint of both value and volume
- Reporting and evaluation of recent industry developments
- Market shares and strategies of key players
- Emerging niche segments and regional markets
- An objective assessment of the trajectory of the market
- Recommendations to companies for strengthening their foothold in the market
Note: Although care has been taken to maintain the highest levels of accuracy in TMR’s reports, recent market/vendor-specific changes may take time to reflect in the analysis.